SMITHKLINE BEECHAM TO PUT MOST OF $1 BIL. RETURN ON SALE OF STERLING's
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE BEECHAM TO PUT MOST OF $1 BIL. RETURN ON SALE OF STERLING's North American OTC business to Bayer AG toward the reduction of debt incurred with the $2.93 bil. purchase of the Sterling Winthrop worldwide OTC business in August and the $2.3 bil. acquisition of Diversified Pharmaceutical Services in May. SmithKline's assumption of more than $5 bil. in debt during 1994 following the Sterling Winthrop acquisition from Kodak moved SB onto Standard & Poor's CreditWatch negative list for possible downgrading of its "AA-" long-term credit rating ("The Tan Sheet" Sept. 5, p. 7).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning